MARKET WIREYahoo • 1d ago
SGIOY vs. UTHR: Which Stock Is the Better Value Option?SGIOY vs. UTHR: Which Stock Is the Better Value Option?
Why UTHR Stock advanced +1.20% Today — RQD Quant Desk Flash
$593.54 +1.20% NASDAQ • Public Delayed / 60s Snapshot
United Therapeutics Corporation (UTHR) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
ROARABLE B- • BUY
Cap $25.46B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
WHALE OPTIONS TUG-OF-WAR:60% Call Buyers ($2.7M)
40% PutsMax Pain: $582.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why UTHR Stock advanced +1.20% Today — RQD Quant Desk Flash
United Therapeutics Corporation (UTHR) advanced +1.20% to $593.54 as options desks priced 60% call premium vs. 40% put protection around the $582 max-pain magnet. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 91% of its 52-week range ($430.02 – $609.99) with RSI-14 at 70.1 (OVERBOUGHT (>70)).
- ▸Whale Options Positioning: $2.7M in bullish call flow vs. $1.8M in put flow (Put/Call 0.67x, implied earnings swing ±6.7%).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 87.9% gross margin and $1.0B annual free cash flow.
Live UTHR Headlines & Catalysts
RISK WATCHYahoo • 1d ago
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesOmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0.00% and +10.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
CATALYSTYahoo • 1d ago
Why Did Insmed Stock Jump?For questions about this article or underlying research, email help@trefis.com.
RISK WATCHYahoo • 2d ago
United Therapeutics (UTHR) Cleared To Start Trial For New Pulmonary Hypertension TherapyUnited Therapeutics (NasdaqGS:UTHR) received FDA clearance to begin clinical trials of Treprostinil-Iloprost SMI for pulmonary arterial hypertension. The investigational therapy pairs two prostacyclin analogues and is de
CATALYSTYahoo • 2d ago
Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”Key TakeawaysInsmed shares jumped 12% after third-quarter revenue of $524. 4 million beat expectations, led by $400.
CATALYSTYahoo • 2d ago
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineCollegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREBenzinga • 3d ago
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
MARKET WIREYahoo • 3d ago
United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH TreatmentUnited Therapeutics Corporation (NASDAQ:UTHR) has received clearance from the U. S.
CATALYSTYahoo • 3d ago
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
CATALYSTYahoo • 3d ago
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forUnited Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live UTHR Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
UTHR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +4.79%⚡ TESTING RESISTANCE
2026-10-30O $600.0H $610.0L $593.6C $598.7VOL 502.8K
RES: $610.5SUP: $452.8SMA50: $527.1SMA200: $531.5
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
UTHR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
12.5%/yr Implied 5Y Growth
vs. +10.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on UTHR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for UTHR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for UTHR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
UTHR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is UTHR stock moving today?
Why UTHR Stock advanced +1.20% Today — RQD Quant Desk Flash. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support.